Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D9O7GC
|
|||
| Drug Name |
GTB-3550
|
|||
| Synonyms |
OXS-3550
Click to Show/Hide
|
|||
| Drug Type |
Recombinant protein
|
|||
| Indication | Acute myelogenous leukaemia [ICD-11: 2A41; ICD-10: C92.2] | Phase 1/2 | [1] | |
| Mast cell leukaemia [ICD-11: 2A21.00; ICD-10: C94.3] | Phase 1/2 | [1] | ||
| Myelodysplastic syndrome [ICD-11: 2A37; ICD-9: 238.7] | Phase 1/2 | [1] | ||
| Systemic mastocytosis [ICD-11: 2A21.0; ICD-9: 202.6, 757.33] | Phase 1/2 | [1] | ||
| Company |
GT Biopharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Immunoglobulin gamma Fc receptor III (FCGR3) | Target Info | Inhibitor | [2] |
| Myeloid cell surface antigen CD33 (CD33) | Target Info | Inhibitor | [2] | |
| KEGG Pathway | Hematopoietic cell lineage | |||
| Reactome | Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03214666) GTB-3550 (CD16/IL-15/CD33) Tri-Specific Killer Engager (TriKE) for High Risk Heme Malignancies. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of GT Biopharma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.